Improving cancer immunotherapy based on anti-PD-1 and STING agonists by combining small innovative molecule

Project Details

Description

The revolution of Immune-checkpoint blockade-based cancer immunotherapy is in the process to fundamentally reshaping the treatment of cancer. This enthusiastic vision has been seriously tempered by the clinical reality that few patients benefit from the remarkable clinical remissions whereas the majority has a short-term benefit or no benefit at all. To broaden the use of immunotherapy, research is now pushing towards combining immunotherapy with other anti-cancer therapies. SMART COMBO project will assess the therapeutic benefit of innovative immunotherapy combination with smart molecules modulating the immune landscape of tumors by switching cold to hot tumor microenvironment. Fueled by synergistic cooperation between LIH-TIME group and Sprint Bioscience Pharma Company, this project will contribute to extend the benefit of immunotherapy by developing smart combinatorial approaches that might create tremendous enthusiasm in anticancer care.
AcronymSMART COMBO
StatusActive
Effective start/end date15/07/2114/07/23

Funding

  • FNR - Fonds National de la Recherche: €150,673.00

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.